Company / Current Liabilities per Share
Celldex Therapeutics, Inc. Current Liabilities per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities per Share
$0.77
FY2025
5-year range
$0.35 / $0.77
FY2021-FY2025
Trend
+28.7%
vs FY2024
Sector context
#143 of 159
Health Care
What the data says
Among 159 Health Care companies, Celldex Therapeutics, Inc. is in the top 10% for current liabilities per share. Current Liabilities per Share has increased for 4 consecutive years, from $0.35 in FY2021 to $0.77 in FY2025.
Based on SEC 10-K filings.
0.77 in FY2025 with a 5-year CAGR of +16.4%.
Increased from $0.56 to $0.77 over the past 2 years.
Health Care sector context is included.
Current Liabilities per Share over time
Growth rates
- 3-Year CAGR
- +24.8%
- 5-Year CAGR
- +16.4%
- 10-Year CAGR
- -
Sector benchmark
Top 10% in Health CareTop 10% of 159This company $0.77 Sector average $29.89
▼
-97.4% below sector average
Key checks
Key Insights
- Celldex Therapeutics, Inc.'s current liabilities per share has grown for 4 consecutive years.
- In FY2025, current liabilities per share increased 28.7% year-over-year.
- Ranks #143 out of 159 companies in the Health Care sector.
- Peak current liabilities per share was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.40 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current Liabilities per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.77 | +28.7% |
| FY2024 | $0.60 | +6.9% |
| FY2023 | $0.56 | +41.3% |
| FY2022 | $0.39 | +11.5% |
| FY2021 | $0.35 | -1.4% |
| FY2020 | $0.36 | -47.7% |
| FY2019 | $0.69 | -49.7% |
| FY2018 | $1.36 | +493.0% |
| FY2017 | $0.23 | -21.3% |
| FY2016 | $0.29 | -4.6% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026